Open access
Open access
Powered by Google Translator Translator

Vaccines

Cohort Study: Effectiveness of homologous vs. heterologous booster doses for an inactivated SARS-CoV-2 vaccine.

26 Apr, 2022 | 08:06h | UTC

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study – The Lancet Global Health

Commentaries:

COVID-19 vaccine booster strategy: striving for best practice – The Lancet Global Health

Covid-19: Mix and match booster vaccination approach offers best protection, study reports – The BMJ

 

Commentary on Twitter

 

Studies highlight meningitis vaccine’s potential against gonorrhea.

20 Apr, 2022 | 10:06h | UTC

Commentary: Studies highlight meningitis vaccine’s potential against gonorrhea – CIDRAP

News Release: Threat of untreatable gonorrhoea could be tackled using an existing meningitis vaccine – The Lancet

Study 1: Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study – The Lancet Infectious Diseases (link to abstract – $ for full-text)

Study 2: Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study – The Lancet Infectious Diseases (link to abstract – $ for full-text)

Study 3: Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis – The Lancet Infectious Diseases

 

Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial.

19 Apr, 2022 | 02:25h | UTC

Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial – Reuters

 

Commentary on Twitter

 

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease.

19 Apr, 2022 | 02:14h | UTC

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease – Open Forum Infectious Diseases

 

Commentary on Twitter

 

M-A: Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination.

18 Apr, 2022 | 10:32h | UTC

Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Commentaries:

Myopericarditis following COVID-19 vaccination is rare, finds international study – The Lancet

Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented – The Lancet Respiratory Medicine

Study explores myopericarditis incidence and COVID-19 vaccination – News Medical

 

Commentary on Twitter

 

A nationwide observational analysis in Israel showed a fourth dose of the Pfizer vaccine may reduce the short-term risk of Covid-19–related outcomes.

14 Apr, 2022 | 08:51h | UTC

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting – New England Journal of Medicine

Editorial: Covid-19 Boosters — Where from Here?

Related:

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter

 

RCT: Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children.

14 Apr, 2022 | 08:43h | UTC

Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

RCT: Single-dose HPV vaccination found effective among young African women.

12 Apr, 2022 | 10:08h | UTC

Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women – NEJM Evidence

News Releases:

Study boosts support for single-dose HPV vaccine regimen – University of Washington

One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer – World Health Organization

Related:

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

 

Commentary on Twitter (thread – click for more)

 

M-A: Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia.

8 Apr, 2022 | 10:50h | UTC

Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis – International Journal of Infectious Diseases

Related:

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

Review: Vaccine-induced immune thrombotic thrombocytopenia.

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

7 Apr, 2022 | 10:00h | UTC

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Related:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter (thread – click for more)

 

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

5 Apr, 2022 | 09:46h | UTC

The Evidence On 4th Doses of Covid Vaccines & the Thorny Question of Age Thresholds – Absolutely Maybe Blog, by Hilda Bastian

Related:

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter

 

RCT: Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D).

5 Apr, 2022 | 08:50h | UTC

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India – The Lancet

Invited Commentary: DNA vaccines join the fight against COVID-19 – The Lancet

 

Commentary on Twitter

 

Case-control study: In children 5 to 11 years of age, the Pfizer vaccine showed an effectiveness of 68% against hospitalization caused by the Omicron variant.

31 Mar, 2022 | 08:37h | UTC

BNT162b2 Protection against the Omicron Variant in Children and Adolescents – New England Journal of Medicine

Commentary: COVID vaccination of children age 5-11 cut omicron hospitalizations by 68% – Children’s Hospital Boston

Related: [Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.

 

Commentary on Twitter

 

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

30 Mar, 2022 | 10:44h | UTC

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Commentaries:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical

 

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

30 Mar, 2022 | 10:42h | UTC

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

See Guidance: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

 

Opinion: Global vaccination must be swifter.

29 Mar, 2022 | 10:12h | UTC

Global vaccination must be swifter – Nature

 

Moderna to ask FDA to authorize Covid-19 vaccine in children 6 months to 6 years.

28 Mar, 2022 | 10:01h | UTC

Moderna to ask FDA to authorize Covid-19 vaccine in children 6 months to 6 years – STAT

 

Retrospective Cohort: A population-based study in Sweden and Norway did not find an increased risk of pregnancy complications after COVID-19 vaccination.

28 Mar, 2022 | 09:51h | UTC

Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes – JAMA

See also: Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes – JAMA

Editorial: COVID-19 mRNA Vaccines During Pregnancy: New Evidence to Help Address Vaccine Hesitancy – JAMA

News Release: No increase in pregnancy complications after COVID-19 vaccination – Karolinska Institutet

 

[Preprint] Risk of death following SARS-CoV-2 infection or COVID-19 vaccination in young people in England: a self-controlled case series study.

25 Mar, 2022 | 09:47h | UTC

Risk of death following SARS-CoV-2 infection or COVID-19 vaccination in young people in England: a self-controlled case series study – medRxiv

 

Commentary on Twitter

 

RCT: Safety and efficacy of a third dose of the Pfizer Covid-19 vaccine during the Delta wave.

24 Mar, 2022 | 09:46h | UTC

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine – New England Journal of Medicine

 

Commentary on Twitter

 

Effectiveness of the Johnson & Johnson vaccine in health-care workers in South Africa in a period when the beta and then the delta SARS-CoV-2 variants of concerns were dominant.

21 Mar, 2022 | 09:43h | UTC

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study – The Lancet

Invited Commentary: Sisonke: reaching several goals together – The Lancet

 

Commentary on Twitter (thread – click for more)

 

Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.

21 Mar, 2022 | 09:37h | UTC

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel – JAMA

Related:

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Study finds no increased risk of rare neurological events after covid vaccination.

18 Mar, 2022 | 09:31h | UTC

News Release: Study finds no increased risk of rare neurological events after covid vaccination – BMJ Newsroom

Original Study: Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis – The BMJ

Editorial: The neurological safety of covid-19 vaccines

 

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

17 Mar, 2022 | 09:12h | UTC

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron – New England Journal of Medicine

Related: [Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

 

Effectiveness of the Sputnik V, AstraZeneca, and Sinopharm vaccines for the risk of infection and death due to COVID-19 in people older than 60 years in Argentina.

17 Mar, 2022 | 09:10h | UTC

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study – The Lancet

Commentary: Evaluating COVID-19 vaccines in the real world – The Lancet

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.